Combination immunotherapy for recurrent glioblastoma after bevacizumab
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of two drugs for people with glioblastoma that has come back after treatment with bevacizumab (a drug that targets blood vessel growth). The goal is to see if this new combination can shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of glioblastoma (a type of brain cancer).
- Your tumor must have returned after previous treatment, and you must have had at least one recurrence.
- You must have had surgery at Henan Provincial People's Hospital, and during that surgery a small device (reservoir) was placed under your scalp to collect fluid from the surgical cavity.
- You must be able to have MRI scans and fluid collection from the device as part of the study.
- You must be generally well enough to carry out daily activities (KPS score 70 or higher).
- You must not have had more than two recurrences of your tumor, and no spread of tumor to other parts of the body or the spinal fluid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (a drug that blocks blood vessel growth to tumors)—for people with astrocytoma that has come back. The goal is to see if this combination can slow or stop the tumor's growth.
This Phase 2 trial tests an immune treatment (sintilimab, an anti–PD-1 antibody) together with low-dose bevacizumab (Avastin) to treat oligodendroglioma that has come back, including cases detected by tumor DNA in body fluid. It aims to slow or control tumor growth and help reduce symptoms by targeting both the tumor and its blood supply.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.